Zota Health Care Ltd.
Snapshot View

243.75 +5.10 ▲2.1%

26 July 2021, 03:57:24 P.M.
Volume: 34,424

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.zotahealthcare.com
Financial Indicators
Market Cap 598.66 Cr.
Earnings per share (EPS) -0.09 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 26.99 Trailing Twelve Months Ending 2021-03
Price to Book Value 9.03 Calculated using Price: 243.75
Dividend Yield 0.41 Period Ending 2020-03
No. of Shares Subscribed 2.46 Cr. 24,560,327 Shares
FaceValue 10
Company Profile

Zota Health Care was originally incorporated on July 12, 2000 vide Certificate of Incorporation issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. It is a pharmaceutical company, engaged in developing, manufacturing and marketing pharmaceutical products. The company mainly market generic, patented and OTC pharmaceutical products, which it commercializes through the network of its distributor channel for its domestic sales.

The company started operations in 2000 by marketing pharmaceutical products on a local level. Over the years the company has built a steady position for itself in the domestic market. The backbone of the company’s revenue from operations is its distribution network, team of medical representatives and its marketing team. In addition to being vast, the company’s product portfolio is also diversified in nature, with its offerings ranging from allopathic medicine to ayurvedic to healthcare products. It offers varieties of tablets, capsules, ointments, oral liquids, injectable to meet customer needs. The company has also ensured to have its presence spread throughout the country and has achieved the same by supplying in all the 4 regions of the country. The company has applied for patent of 19 unique formulations, wherein it has been granted approvals for 6 formulations.

The company has also taken initiatives for digital marketing strategy and has already launched a mobile application for its division ‘Nutravedic.com’ and is in process of launching another application to integrate the markets and reach customers at large. Further, it has purchased the marketing rights of Astra-Idl for a period of three years to strengthen its market segment of generic medicines.

Business area of the company

Zota Health Care manufactures and markets pharmaceutical formulations, nutraceutical, and ayurvedic medicines in India and internationally. They mainly market generic, patented and OTC pharmaceutical products. Products are marketed in the form of tablets, capsules, ointment, oral liquids, injectable etc as per customers need.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.14%
1 Week
-2.13%
1 Month
+22.21%
3 Month
+57.31%
6 Month
+52.25%
1 Year
+72.57%
2 Year
+17.75%
5 Year
2 years 2019-03 2020-03
Return on Equity (%) 8.05 3.98
Return on Capital Employed (%) 11.45 5.71
Return on Assets (%) 6.19 3.08

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 69 69
Non Curr. Liab. 1 1
Curr. Liab. 20 19
Minority Int.
Equity & Liab. 90 88
Non Curr. Assets 27 30
Curr. Assets 62 59
Misc. Exp. not W/O
Total Assets 90 88

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 86 95
Other Income 2 2
Total Income 87 97
Total Expenditure -78 -91
PBIDT 9 6
Interest 0 0
Depreciation -1 -2
Taxation -2 -1
Exceptional Items
PAT 6 3

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -3 6
Cash Fr. Inv. 9 -4
Cash Fr. Finan. -6 -3
Net Change -1 -1
Cash & Cash Eqvt 2 1

Shareholding Pattern View Details

9 Qtrs 2019-03 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 67.75 69.67 69.92 69.93 69.93 69.93 69.95 69.97 69.95
Public 32.25 30.33 30.08 30.07 30.07 30.07 30.05 30.03 30.05
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.04 0.04 0.04 0.04

Announcements View Details

Thu, 15 Jul 2021
Clarification - Financial Results
The Exchange has sought clarification from Zota Health Care LImited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Wed, 14 Jul 2021
Clarification - Financial Results
The Exchange has sought clarification from Zota Health Care LImited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Fri, 09 Jul 2021
Updates
Zota Health Care LImited has informed the Exchange regarding 'Capacity Addition at Company's manufacturing plant situated at Surat Special Economic Zone'.

Technical Scans View Details

Fri, 23 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 703.40 +1.4%
Divi's Laboratories Ltd. 128,088.59 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,411.25 -0.2%
Cipla Ltd. 76,510.04 950.55 +0.3%
Cadila Healthcare Ltd. 62,965.29 605.55 -1.6%
Aurobindo Pharma Ltd. 56,484.48 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. 56,291.69 4,100.95 +4.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.81 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 4,100.95 +4.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.17 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 4,100.95 +4.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%